Sterling Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Sterling Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.28K	Sell	1,398 -31	-2%	-$159	﹤0.01%	2683
2026 Q2	$6.64K	Sell	1,429 -889	-38%	-$4.42K	﹤0.01%	2460
2026 Q1	$12.5K	Sell	2,318 -1,779	-43%	-$8.17K	﹤0.01%	2260
2025 Q4	$14.6K	Sell	4,097 -1,192	-23%	-$3.79K	﹤0.01%	2403
2025 Q3	$15.3K	Buy	5,289 +3,109	+143%	+$10.6K	﹤0.01%	2264
2025 Q2	$7.85K	Buy	2,180 +849	+64%	+$2.53K	﹤0.01%	2277
2025 Q1	$3.98K	Sell	1,331 -1,141	-46%	-$3.56K	﹤0.01%	2278
2024 Q4	$8.28K	Buy	2,472 +2,227	+909%	+$7.4K	﹤0.01%	2248
2024 Q3	$821	Buy	+245	New	+$888	﹤0.01%	2641

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Sterling Capital Management's AVIR Position: Q3 2026 in Review

Sterling Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 2.2% in Q3 2026, selling an estimated $159 and leaving 1,398 shares worth $7.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Sterling Capital Management first reported a position in AVIR in Q3 2024 and has held it in 9 quarters since. The position peaked at $15.3K in Q3 2025. 80 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

Sterling Capital Management held 1,398 shares of Atea Pharmaceuticals worth $7.28K as of Q3 2026.
Sterling Capital Management sold 31 Atea Pharmaceuticals shares in Q3 2026, an estimated $159.
Atea Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2683 holding.
Sterling Capital Management first reported a position in Atea Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's Atea Pharmaceuticals position peaked at $15.3K in Q3 2025.
80 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.